An unusual ovarian neoplasm diagnosed in a patient with rupture of unicornuate uterus during pregnancy: a case report

Unicornuate uterus is a rare disease characterized with reduced fertility, and ovarian tumor diagnosed during pregnancy is uncommon as well. These two diseases have been reported separately. However, patient suffering from both diseases has never been reported before. The authors herein report a case of a 32-year-old Chinese woman presenting with a unicornuate uterus with no horn, who suffered from acute abdominal pain and intra-abdominal hemorrhage at 26 weeks gestation. Incidentally, a borderline ovarian tumor (BOT) and rupture of uterus were found during an urgent exploratory laparotomy. During the follow-up, ovarian tumor recurred in the first year after the operation. The authors suggest that BOT with micropapillary patterns should be paid much more attention to, other than only assessing the histological type. Furthermore, they also suggest that a slightly increased in serum CA-125 value should not be ignored.

Urogenital abnormalities; Uterine rupture; Pregnancy; Ovarian neoplasms; Recurrence.

[1] Jayaprakasan K., Chan Y.Y., Sur S, Deb S., Clewes J.S., Raine-Fenning N.J.: “Prevalence of uterine anomalies and their impact on early pregnancy in women conceiving after assisted reproduction treatment”. Ultrasound Obstet. Gynecol., 2011, 37, 727.

[2] Akar M.E., Bayar D., Yildiz S., Ozel M., Yilmaz Z.: “Reproductive outcome of women with unicornuate uterus”. Aust. N. Z. J. Obstet. Gynaecol., 2005, 45, 148.

[3] Grimm D., Woelber L., Trillsch F., Keller-v Amsberg G., Mahner S.: “Clinical management of epithelial ovarian cancer during pregnancy”. Eur. J. Cancer, 2014, 50, 963.

[4] Abascal-Saiz A., Sotillo-Mallo L., de Santiago J., Zapardiel I.: “Management of borderline ovarian tumours: a comprehensive review of the literature”. Ecancermedicalscience, 2014, 8, 403.

[5] Reichman D., Laufer M.R., Robinson B.K.: “Pregnancy outcomes in unicornuate uteri: a review”. Fertil. Steril., 2009, 91, 1886.

[6] Fauvet R., Brzakowski M., Morice P., Resch B., Marret H., Graesslin O., Darai E.: “Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study”. Ann. Oncol., 2012, 23, 1481.

[7] Morice P., Camatte S., El H.J., Pautier P., Duvillard P., Castaigne D.: “Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors”. Fertil. Steril., 2001, 75, 92.

[8] Vasconcelos I., de Sousa M.M.: “Conservative surgery in ovarian borderline tumours: A meta-analysis with emphasis on recurrence risk”. Eur. J. Cancer, 2015, 51, 620.

[9] Palomba S., Zupi E., Russo T., Falbo A., Del N.S., Manguso F., et al.: “Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study”. Hum. Reprod., 2007, 22, 578.

[10] Yinon Y., Beiner M.E., Gotlieb W.H., Korach Y., Perri T., Ben- Baruch G.: “Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors”. Fertil. Steril., 2007, 88, 479.

[11] Song T., Hun C.C., Lee Y.Y., Kim T.J., Lee J.W., Bae D.S., Kim B.G.: “Oncologic and reproductive outcomes of cystectomy compared with oophorectomy as a treatment for borderline ovarian tumours”.Hum. Reprod., 2011, 26, 2008. [12] Shih K.K., Zhou Q., Huh J., Morgan J.C., Iasonos A., Aghajanian C., et al.: “Risk factors for recurrence of ovarian borderline tumors”. Gynecol. Oncol., 2011, 120, 480.

[13] Bell D.A., Longacre T.A., Prat J., Kohn E.C., Soslow R.A., Ellenson L.H., et al.: “Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives”. Hum. Pathol., 2004, 35, 934.

[14] May T., Virtanen C., Sharma M., Milea A., Begley H., Rosen B., et al.: “Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary”. Gynecol. Oncol., 2010, 117, 9.

[15] Morice P., Uzan C., Fauvet R., Gouy S., Duvillard P., Darai E.: “Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence”. Lancet Oncol., 2012, 132, 23.

[16] Faluyi O., Mackean M., Gourley C., Bryant A., Dickinson H.O.: “Interventions for the treatment of borderline ovarian tumours”. Cochrane Database Syst Rev., 2010, 9, CD007696.

[17] Leary A., Petrella M.C., Pautier P., Duvillard P., Uzan C., Tazi Y., et al.: “Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants”. Gynecol. Oncol., 2014, 132, 23.

[18] Vasconcelos I., Olschewski J., Braicu I., Sehouli J.: “A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants”. Oncologist, 2015, 20, 151.

[19] Marret H., Lhomme C., Lecuru F., Canis M., Leveque J., Golfier F., Morice P.: “Guidelines for the management of ovarian cancer during pregnancy”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 149, 18.

[20] Anastasi E., Porpora M.G., Pecorella I., Bernardo S., Frati L., Benedetti P.P., Manganaro L.: “May increased CA125 in borderline ovarian tumor be indicative of a poor prognosis? A case report”. Tumour Biol., 2014, 35, 6969.